RMC-6236

DRUG8 trials

Sponsors

Revolution Medicines Inc., Revolution Medicines, Inc., Amgen, Tango Therapeutics, Inc.

Conditions

Advanced Gastrointestinal, Biliary Tract, and Pancreatic CancersAdvanced Solid TumorsCRCColorectal CancerColorectal Cancer (CRC)Gastrointestinal CancerKRAS G12C-mutated Solid Tumors, Lung CancerKRAS, NRAS, HRAS-mutated NSCLC

Phase 1

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

RecruitingNCT05379985

Revolution Medicines, Inc.Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) +1

Start: 2022-05-31End: 2027-07-26Target: 754Updated: 2026-05-15

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

RecruitingNCT06040541

Revolution Medicines, Inc.Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) +1

Start: 2023-09-07End: 2027-04-30Target: 604Updated: 2026-06-03

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

RecruitingNCT06162221

Revolution Medicines, Inc.Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer +2

Start: 2024-01-18End: 2028-12-01Target: 616Updated: 2026-06-30

A Study Evaluating Anvumetostat in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103)

Active, not recruitingNCT06360354

AmgenAdvanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers

Start: 2024-05-29End: 2026-11-30Updated: 2026-06-01

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

RecruitingNCT06445062

Revolution Medicines, Inc.Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma +3

Start: 2024-05-24End: 2027-07-15Target: 1130Updated: 2026-07-29

Study of RMC-6291, With or Without RMC-6236, in Combination With Other Anti-Cancer Agents, in Patients With RAS G12C-Mutated Non-Small Cell Lung Cancer – Subprotocol A

RecruitingCTIS2023-509571-16-00

Revolution Medicines Inc.Lung Cancer

Start: 2024-07-17Target: 162Updated: 2025-12-17

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

RecruitingNCT06922591

Tango Therapeutics, Inc.PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC +5

Start: 2025-05-31End: 2027-12-01Target: 183Updated: 2026-05-14

Phase 3

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Active, not recruitingNCT06625320

Revolution Medicines, Inc.Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma

Start: 2024-10-16End: 2027-12-01Updated: 2026-06-02

Related Papers

Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the phase 3 RASolute 302 study.

Journal of Clinical Oncology2026-06-03

Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.

2026-05-31

Safety and efficacy of daraxonrasib monotherapy as later-line (3L+) treatment for patients (pts) with metastatic pancreatic adenocarcinoma (PDAC).

Journal of Clinical Oncology2026-05-28

Abstract CT021: Preliminary safety and clinical activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer (NSCLC)

Cancer Research2026-05-15

Abstract CT215: RASolve 301: A Phase 3 study of daraxonrasib (RMC-6236) vs. docetaxel in patients with previously treated RAS-mutant NSCLC

Cancer Research2026-04-17

Abstract LB337: Daraxonrasib monotherapy as first-line (1L) treatment for patients with metastatic pancreatic adenocarcinoma (mPDAC)

Cancer Research2026-04-17

Abstract LB407: Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

Cancer Research2026-04-17

Abstract 7065: Targeting MTAP-deleted/KRAS mutant cancers using RAS inhibitors in combination with AMG 193, an MTA-cooperative PRMT5 inhibitor.

Cancer Research2026-04-03

Abstract B046: Pan-RAS Inhibition as a novel therapeutic strategy for RAS-driven rhabdomyosarcoma

Cancer Research2026-03-05

Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination Strategies

Molecular Cancer Therapeutics2025-10-22

Abstract A118: Daraxonrasib, a RAS(ON) multi-selective inhibitor, exhibits potent antitumor activity and combinatorial benefit with standard of care chemotherapy and with anti-PD-1 in preclinical models of KRAS G12R PDAC

Cancer Research2025-09-28

A neomorphic protein interface catalyzes covalent inhibition of RAS <sup>G12D</sup> aspartic acid in tumors

Science2025-07-2414 citations

Trial in progress: RASolute 302—A phase 3, multicenter, global, open-label, randomized study of daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor, versus standard of care chemotherapy in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2025-05-285 citations

Abstract CT019: Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors

Cancer Research2025-05-224 citations

Abstract LB218: Early reduction in circulating tumor DNA (ctDNA) is associated with clinical activity of daraxonrasib (RMC-6236) in RAS mutant non-small cell lung cancer (NSCLC)

Cancer Research2025-04-25

Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers

Journal of Medicinal Chemistry2025-03-0832 citations

Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers

Journal of Medicinal Chemistry2025-02-2422 citations

Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC).

Journal of Clinical Oncology2025-01-2724 citations

Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.

Journal of Clinical Oncology2025-01-2712 citations

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Cancer Discovery2024-04-09213 citations

8 more papers not shown